Form 4: Chimerix Director Disposes of Stock Options Following Merger with Jazz Pharmaceuticals

Director Pratik S. Multani reports the disposal of employee stock options in Chimerix following the company's merger with Jazz Pharmaceuticals, where Chimerix became a wholly-owned subsidiary.

Summary

• Pratik S. Multani, a director of Chimerix, filed a Form 4 detailing changes in beneficial ownership following the merger of Chimerix with Jazz Pharmaceuticals.
• The merger was executed via a tender offer where Jazz Pharmaceuticals offered $8.55 per share for all outstanding shares of Chimerix.
• The tender offer expired on April 17, 2025, and the merger was completed on April 21, 2025.
• As a result of the merger, Multani's employee stock options were affected.
• In-the-money options were accelerated, fully vested, and then cancelled, with Multani receiving a cash payment equal to the difference between the offer price and the exercise price of the options.
• Multani disposed of multiple employee stock option holdings with varying exercise prices and expiration dates.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing related to a merger. While the merger itself could be viewed positively, this specific filing is neutral in tone and simply reports the transaction. The sentiment is slightly positive due to the successful completion of the merger.

Future Outlook

The document does not contain any specific forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects a common scenario in mergers and acquisitions, where outstanding stock options are addressed as part of the deal's terms. The treatment of options (cashing out in-the-money options) is standard practice to ensure fair compensation to employees and directors holding such options.

Comparison to Industry Standards

• The merger consideration of $8.55 per share is a key metric, but without knowing Chimerix's financials, it's difficult to compare to industry standards.
• Comparable companies that have been acquired recently include Array BioPharma acquired by Pfizer for $11.4 billion, which represented a premium of 62% to Array's closing price prior to the announcement.
• The treatment of stock options in this merger is standard practice, similar to how options were handled in the acquisition of Juno Therapeutics by Celgene, where vested options were cashed out.

Stakeholder Impact

• Shareholders received $8.55 per share as part of the merger agreement.
• Option holders with in-the-money options received a cash payment based on the difference between the offer price and the exercise price.
• Chimerix became an indirect wholly-owned subsidiary of Jazz Pharmaceuticals, impacting the company's organizational structure.

Key Dates

Keywords

Merger, Chimerix, Jazz Pharmaceuticals, Stock Options, Form 4, Beneficial Ownership, Director, Tender Offer